Background
Type 2 diabetes mellitus (DM) is a common metabolic disease with an increasing worldwide prevalence rate of 8.3% [
1], and with 11% among Korean male adults. Considering that more than 9 million osteoporotic fractures are recorded annually worldwide, osteoporosis is a significant contributor to morbidity and lost life years globally [
2]. Osteoporosis and type 2 DM share many common characteristics in that they are both chronic diseases with an increasingly global medical burden.
Although individuals with type 1 DM show decreased bone mass density (BMD), those with type 2 DM often have normal or even slightly elevated BMD compared with an age-matched control population [
3]. Bone fragility results from decreased bone mineral mass and alterations in bone microstructure. Multiple mechanisms can contribute to increased fractures in type 2 DM patients. Glucose toxicity, lack of insulin and other factors affects bone metabolism. A substantial number of studies examined the association between type 2 DM and fracture risk [
4,
5]. Longer type 2 DM duration increases diabetic complications, insulin usage, and fracture risk and results in inadequate glucose control. Clinically, assessing the bone microstructure of type 2 DM patients is difficult because CT or MRI should be used [
3]. Therefore determining the BMD is the best approach for now.
The prevention of fractures is an important goal for studies concerning older adults. Many studies focus on osteoporosis in women. However, as many as one in four men aged > 50 years will develop at least one osteoporosis-related fracture in his lifetime, highlighting the need for more studies on osteoporosis in men [
6]. One in three men die in within a year after a hip fracture, another one in three experience a subsequent fracture again [
7]. Generally, men have worse smoking and alcohol drinking habits and higher risk of fall than women [
8], which may contribute to bone health deterioration. Furthermore, men are approximately 70% less frequently screened for osteoporosis than women [
9]. For individuals aged ≥50 years in Korea, the prevalence rates of osteoporosis and osteopenia are 7.3% and 38.0% in men and 46.5% and 48.7% in women, respectively [
10]. In another Korean study, only 7.6% of men found out that they had osteoporosis, and only 5.7% of them had their disease treated [
11].
In light of public health, male osteoporosis associated with type 2 DM should be carefully considered. The present study aimed to assess the association between BMD and type 2 DM status by considering several confounding factors such as age, body mass index (BMI), and fasting insulin and glucose level. We hypothesized that participants with longer duration of type 2 DM may have lower BMD because of poor disease control and insulin deficiency.
Discussion
In the present study, the prediabetic and diabetic groups had higher mean BMDs at all measured sites than the control group. The BMDs in men with prediabetes were similar to those in men with diabetes in all cases. However, men with diabetes with a disease duration of > 5 years had lower mean femoral neck BMDs than those with a disease duration of ≤5 years after adjustment for all clinically relevant covariates.
Asian people develop diabetes at a lower degree of obesity and at younger ages and experience chronic diabetic complications [
18]. In addition, some studies in Japan [
19] and Korea [
20] have showed that Asian patients with type 2 DM have lower BMI and decreased β-cell function compared with European and American patients. Current study showed that each groups had similar BMI in overweight range, but not obesity. Therefore a study on the relationship between type 2 diabetes and osteoporosis in Asian population would be good in isolating the effect of obesity.
The association between BMD and type 2 DM remains unclear. However, the results of the current study are consistent with those of previous studies in that DM patients have higher BMDs [
21‐
23]. This study showed that men with prediabetes had higher BMDs than controls. Moreover, in this study, men with prediabetes and DM showed similar fasting insulin levels. Excessively high insulin level in the blood has been reported to be associated with increased bone mass [
24] because of the anabolic effects of insulin [
25] and increase in free sex hormone levels [
26]. Although prediabetes is not considered a disease, insulin resistance in prediabetes will affect bone mass and microstructure [
12].
Bone fragility results from decreased BMD and alterations in bone microstructure [
3]. Assessing the macrogeometry of cortical bone and the microarchitecture of the trabecular bone is difficult owing to the use of quantitative CT or MRI. In clinical setting, the gold standard of bone strength measurement is DXA and BMD remains a significant predictor of fracture risk in type 2 DM, that is, independent of trabecular bone score and DM itself [
27].
Elevated fasting insulin levels play a key role in DM development, and they mostly result in increased bone mass. In complicated conditions, such as advanced type 2 DM, elevated insulin levels have an unexpected effect. As insulin resistance increases, the fasting insulin levels are inversely related to BMD, and this relationship becomes more significant as the degree of insulin resistance increases [
12]. In advanced type 2 DM requiring insulin, pancreatic ß- cell function certainly decreased. However, the exact timing of this phenomenon remains to be determined. A Korean prospective cohort study [
20] reported on the role of ß-cell dysfunction on DM development, focusing on Asian populations. Insulin levels possibly increased and then decreased at some point, and the bone density may have become weak at this point.
In the present study, insulin levels were similar in prediabetes and diabetes and in two groups with different duration of disease. It was significantly different that fasting glucose levels in prediabetes and diabetes, and HbA1c levels between men with diabetes duration of ≤5 years and those with diabetes duration > 5 years. High blood glucose induces formation of advanced glycation end-products (AGE), with negative effects on structural proteins such as type I collagen, the main bone matrix protein. AGE may also reduce bone strength by impairing bone formation [
28]. Most of the recent studies have confirmed decreased levels of bone turnover markers in patients with DM [
3]. The previous research on mechanisms of type 2 DM showed that action on bone with long-term high glucose levels could lower the turnover, resulting in unfavorable bone balance.
Researchers have generally neglected osteoporosis in men for some time, and many studies have focused on women as participants. One study showed that non-obese women with type2 DM had lower BMD than control participants matched for BMI [
29]. In the present study, we investigated the correlation between BMD and BMI in the group with DM. Our results confirmed the absence of such a correlation. Obese patients with type 2 DM have increased BMD, and evidence indicates that older white women, but not men or black women, with diabetes exhibited more rapid bone loss at the femoral neck and total hip than those with normal glucose homoeostasis [
30]. Type 2 DM has been associated with higher bone loss at the femoral neck than at the total hip in white women even after adjusting for weight loss. Although white women with type 2 DM had higher baseline BMDs, they still exhibited increased bone loss rate, particularly at the femoral neck, than those with normal glucose homoeostasis. This seemingly contradictory finding of higher cross-sectional BMD being associated with more rapid bone loss may reflect the net result of the positive effects of excessive weight and hyperinsulinemia on bones combined with the negative effects of longer diabetes duration [
31].
Possible explanations for significant reduction of femoral BMD are existing literature on bone loss and cortical porosity. Pentosidine is the best-studied AGEs to date. The content of pentosidine in cortical and trabecular bone was higher in patients with femoral neck fractures than in age-matched controls [
3]. These women with prior fractures have significantly lower femoral neck volumetric BMD, a trend towards larger bone volume and thinner cortices on quantitative CT, and higher serum levels of sclerostin than women with diabetes without fractures and nondiabetic controls with fractures(increases of 31.4% and 25.2%, respectively) [
32].
Patients with type 2 DM have a significantly higher fracture risk than the general population [
3,
5]. Men with type 2 DM have lower muscle mass and strength, contributing to the higher incidence of falls and fractures observed in type 2 DM patients [
33]. Hip fracture is the most serious osteoporotic fracture, and our study shows that the femoral neck BMD was lower in the group with a DM duration of > 5 years than in those with a DM duration of ≤5 years. Previous studies showed that patients with type 2 DM have an increased fracture risk in the hip [
5,
22]. Furthermore, another study revealed that women with a DM duration of ≥10 years have particularly high major osteoporotic and hip fracture risks [
33].
This study used relatively large sample sizes representing national population-based data. The sample design and size were also estimated using the methods described in the KNHANES. Therefore, the results can be generalized to whole Korean diabetics. This study is the first to indicate decreased femoral neck BMD in long-time DM in Asia, which is consistent with the findings of previous studies. Current study demonstrated decreased BMD by DXA with duration of type 2 DM different from the earlier studies. However, several limitations should be considered when interpreting the results of this study. The intrinsic nature of cross-sectional design studies precludes this study from conclusively determining any potential causal relationships. The KNHANES was conducted annually, and the subjects were those who were not able to undergo DXA between 2008 and 2011, despite the introduction of DXA in 2008. This study did not consider the anti-diabetic medication in the group with DM; therefore, the effects of drugs are unknown. The reduction in BMD associated with type 2 DM duration requires further study. Five-year type 2 DM duration is a very short period to evaluate its effects on BMD. Moreover, femoral neck BMD decreased in participants with relatively short-term type 2 DM; thus, caution is needed when interpreting the results.